azd8871
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02573155)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd8871
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03645434 | Phase 2 | Sep 14, 2018 | AstraZeneca, Parexel |
| NCT03159442 | Phase 1 | Jun 19, 2017 | AstraZeneca, Covance, Parexel |
| NCT02971293 | Phase 2 | Dec 15, 2016 | AstraZeneca, Parexel, University of Manchester |
| NCT02814656 | Phase 1 | Jun 1, 2016 | AstraZeneca, Parexel |
| NCT02573155 | Phase 1 | Oct 1, 2015 | AstraZeneca, Parexel, University of Manchester |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 5 | 5 | 2 | 2015 |
| Parexel | For profit | 5 | 0 | 2 | 2015 |
| University of Manchester | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Covance | For profit | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1